ABS-201 in Androgenetic Alopecia

Absci ($ABSI)

Will Absci report a numerical improvement in Target Area Hair Count (TAHC) for ABS-201 in AGA patients by Dec. 31, 2026?

Amount (USD)

To win

$3.23

Create account to trade

Matched news3 items

All news

ABSIJun 24, 6:30 AM

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period First multiple ascending dose

Interim Data • Phase 1Interim data Mon, Jun 8, 2026Exact NCT match: NCT07317544

ABSIMay 7, 4:06 PM

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval Initiated dosing of first MAD cohort of

Interim Data • Phase 1Matched abs-201, androgenetic, alopecia, anti-prlr, antibody

ABSIMar 24, 4:05 PM

Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates follicle stem cell niche Appointed seasoned biopharmaceutical

Interim Data • Phase 1Matched abs-201, androgenetic, alopecia, anti-prlr, antibody